Comparison of Shape-Matching and Docking as Virtual Screening Tools

OpenEye Scientific Software, Santa Fe, New Mexico 87507, USA.
Journal of Medicinal Chemistry (Impact Factor: 5.48). 02/2007; 50(1):74-82. DOI: 10.1021/jm0603365
Source: PubMed

ABSTRACT Ligand docking is a widely used approach in virtual screening. In recent years a large number of publications have appeared in which docking tools are compared and evaluated for their effectiveness in virtual screening against a wide variety of protein targets. These studies have shown that the effectiveness of docking in virtual screening is highly variable due to a large number of possible confounding factors. Another class of method that has shown promise in virtual screening is the shape-based, ligand-centric approach. Several direct comparisons of docking with the shape-based tool ROCS have been conducted using data sets from some of these recent docking publications. The results show that a shape-based, ligand-centric approach is more consistent than, and often superior to, the protein-centric approach taken by docking.

Download full-text


Available from: Paul C D Hawkins, Jul 21, 2015
  • Source
    • "The structured knowledge of the binding capabilities of the active site residues to specific groups on the agonist or antagonist leads to proposals for synthesis of very specific agents with a high probability of biological action (Abraham, 2003). In recent years, virtual screening has become an important part of the armamentarium of modern drug discovery (Hawkins et al., 2007). The Computer-aided drug design (CADD) has become an indispensable tool in the pharmaceutical industry and academia. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The accurate prediction of the binding modes between the ligand and protein is of fundamental importance in modern structure-based drug design. In this study, computational ligand docking methodology, AutoDock 4.0, based on Lamarckian genetic algorithm was employed for virtual screens of a compound library with 233 entries (Schiff’s bases of γ-amino butyric acid) for novel and selective inhibitors of the enzyme γ-amino butyrate aminotransferase (GABA-AT), a potential anticonvulsant drug target. Considering free energy of binding and inhibition constant (KI) as a criteria of evaluation, a total of 43 compounds were predicted to be potential inhibitors of GABA-AT and 11 compounds displayed greater binding affinities than γ-vinyl GABA, Vigabatrin, a well-known GABA-AT inhibitor. Compound SBG164, a dibenzylideneacetone analog; compound SBG195, a 1-methylanthraquinone analog; and compound SBG110, a fenchone analog were the most potent in inhibiting the GABA-AT, in silico. Putative interactions between GABA-AT and inhibitors were identified by inspection of docking-predicted poses. This understanding of protein–ligand interaction and value of KI imparts impetus to the rapid development of prospective GABA-AT inhibitor. It also helps to eliminate the number of false positives and negatives.
    Medicinal Chemistry Research 10/2011; 21(10). DOI:10.1007/s00044-011-9843-6 · 1.61 Impact Factor
  • Source
    • "Sybyl8.0 was used to build inhibitor templates based on the previously reported APE1 inhibitor (Madhusudan et al, 2005) and three new pharmacophore templates designed in silico (M1, M2 and M3) based on the structural features of the APE1 active site (see results and discussion). Using these templates, ROCS 2.3 (Open Eye Scientific, Santa Fe, NM, USA) (Hawkins et al, 2007) was used to extract pharmacophorically-related (Tanimoto cut-off between 0.6 and 0.75) subsets of compounds from the ZINC database (http://; 2008 version with ca. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Modulation of DNA base excision repair (BER) has the potential to enhance response to chemotherapy and improve outcomes in tumours such as melanoma and glioma. APE1, a critical protein in BER that processes potentially cytotoxic abasic sites (AP sites), is a promising new target in cancer. In the current study, we aimed to develop small molecule inhibitors of APE1 for cancer therapy. An industry-standard high throughput virtual screening strategy was adopted. The Sybyl8.0 (Tripos, St Louis, MO, USA) molecular modelling software suite was used to build inhibitor templates. Similarity searching strategies were then applied using ROCS 2.3 (Open Eye Scientific, Santa Fe, NM, USA) to extract pharmacophorically related subsets of compounds from a chemically diverse database of 2.6 million compounds. The compounds in these subsets were subjected to docking against the active site of the APE1 model, using the genetic algorithm-based programme GOLD2.7 (CCDC, Cambridge, UK). Predicted ligand poses were ranked on the basis of several scoring functions. The top virtual hits with promising pharmaceutical properties underwent detailed in vitro analyses using fluorescence-based APE1 cleavage assays and counter screened using endonuclease IV cleavage assays, fluorescence quenching assays and radiolabelled oligonucleotide assays. Biochemical APE1 inhibitors were then subjected to detailed cytotoxicity analyses. Several specific APE1 inhibitors were isolated by this approach. The IC(50) for APE1 inhibition ranged between 30 nM and 50 μM. We demonstrated that APE1 inhibitors lead to accumulation of AP sites in genomic DNA and potentiated the cytotoxicity of alkylating agents in melanoma and glioma cell lines. Our study provides evidence that APE1 is an emerging drug target and could have therapeutic application in patients with melanoma and glioma.
    British Journal of Cancer 02/2011; 104(4):653-63. DOI:10.1038/sj.bjc.6606058 · 4.82 Impact Factor
  • Source
    • "The conformationally best energy-minimized structure of ifenprodil was chosen as reference compound, and clobenpropit, iodophenpropit, and capsazepine were subjected to conformational search by using OMEGA, version 2.0 (OpenEye Scientific Software, Santa Fe, NM). The resulting confirmations were superimposed with ifenprodil using rapid overlay of chemical structures (ROCS) (Hawkins et al., 2007). Two-Electrode Voltage-Clamp Electrophysiology. "
    [Show abstract] [Hide abstract]
    ABSTRACT: N-Methyl-D-aspartate (NMDA) receptors are ligand-gated ion channels that mediate a slow, Ca(2+)-permeable component of excitatory synaptic transmission in the central nervous system and play a pivotal role in synaptic plasticity, neuronal development, and several neurological diseases. We describe a fluorescence-based assay that measures NMDA receptor-mediated changes in intracellular calcium in a BHK-21 cell line stably expressing NMDA receptor NR2D with NR1 under the control of a tetracycline-inducible promoter (Tet-On). The assay selectively identifies allosteric modulators by using supramaximal concentrations of glutamate and glycine to minimize detection of competitive antagonists. The assay is validated by successfully identifying known noncompetitive, but not competitive NMDA receptor antagonists among 1800 screened compounds from two small focused libraries, including the commercially available library of pharmacologically active compounds. Hits from the primary screen are validated through a secondary screen that used two-electrode voltage-clamp recordings on recombinant NMDA receptors expressed in Xenopus laevis oocytes. This strategy identified several novel modulators of NMDA receptor function, including the histamine H3 receptor antagonists clobenpropit and iodophenpropit, as well as the vanilloid receptor transient receptor potential cation channel, subfamily V, member 1 (TRPV1) antagonist capsazepine. These compounds are noncompetitive antagonists and the histamine H3 receptor ligand showed submicromolar potency at NR1/NR2B NMDA receptors, which raises the possibility that compounds can be developed that act with high potency on both glutamate and histamine receptor systems simultaneously. Furthermore, it is possible that some actions attributed to histamine H3 receptor inhibition in vivo may also involve NMDA receptor antagonism.
    Journal of Pharmacology and Experimental Therapeutics 03/2010; 333(3):650-62. DOI:10.1124/jpet.110.166256 · 3.86 Impact Factor
Show more